SCHEMBL5022176

SCHEMBL5022176

Cc1cc(C(=O)NCC2(N(C)C)CCCC2)cc(C)c1OCc1ccccc1

nearest known ligand 0.77

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
SLC6A5 Q9Y345 8/20 0.77
LMNA P02545 1/20 0.56
TP53 P04637 3/20 0.55
THRB P10828 3/20 0.54
KDM4E B2RXH2 1/20 0.52
TAOK1 Q7L7X3 1/20 0.51
TAOK3 Q9H2K8 1/20 0.51
OPRM1 P35372 1/20 0.50
OPRD1 P41143 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5017438 0.99 SLC6A5 (0.78) SLC6A5LMNATP53THRBKDM4E
SCHEMBL5017330 0.98 SLC6A5 (0.74) SLC6A5LMNATP53THRBKDM4E
SCHEMBL6013403 0.92 SLC6A5 (0.89) SLC6A5LMNATP53THRBKDM4E
SCHEMBL16233249 0.91 SLC6A5 (0.64) SLC6A5LMNATP53THRBKDM4E
SCHEMBL5017542 0.87 SLC6A5 (1.00) SLC6A5LMNATP53KDM4E
Hydrochloric Acid SCHEMBL26654518 0.86 SLC6A5 (1.00) SLC6A5LMNATP53KDM4E
SCHEMBL5022643 0.86 SLC6A5 (1.00) SLC6A5LMNATP53THRBKDM4E
SCHEMBL16233201 0.86 SLC6A5 (0.59) SLC6A5LMNATAOK1TAOK3
SCHEMBL5022321 0.85 SLC6A5 (0.61) SLC6A5LMNATP53THRBKDM4E
SCHEMBL16233224 0.81 HCN1 (0.61) SLC6A5LMNATP53THRBOPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1419138-B1 N- (1-DIMETHYLAMINOCYCLOALKYL)METHYL BENZAMIDE DERIVATIVES ORGANON NV (NL) 2008-10-29 EP claimed
EP-1419138-A1 N- (1-DIMETHYLAMINOCYCLOALKYL)METHYL]BENZAMIDE DERIVATIVES Akzo Nobel (NL) 2004-05-19 EP claimed
WO-2003010132-A1 N-[(1-DIMETHYLAMINOCYCLOALKYL)METHYL]BENZAMIDE DERIVATIVES AKZO NOBEL N.V. (NL) 2003-02-06 WO claimed
EP-1419138-B1 N- (1-DIMETHYLAMINOCYCLOALKYL)METHYL BENZAMIDE DERIVATIVES ORGANON NV (NL) 2008-10-29 EP disclosed
US-7126027-B2 N-[(1-dimethylaminocycloalkyl)methyl]benzamide derivatives AKZO NOBEL N.V. (NL) 2006-10-24 US disclosed
US-20040242685-A1 N-[(1-dimethylaminocycloalkyl)methyl]benzamide derivatives N.V. ORGANON (NL) 2004-12-02 US disclosed
EP-1419138-A1 N- (1-DIMETHYLAMINOCYCLOALKYL)METHYL]BENZAMIDE DERIVATIVES Akzo Nobel (NL) 2004-05-19 EP disclosed
WO-2003010132-A1 N-[(1-DIMETHYLAMINOCYCLOALKYL)METHYL]BENZAMIDE DERIVATIVES AKZO NOBEL N.V. (NL) 2003-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242685-A1 N-[(1-dimethylaminocycloalkyl)methyl]benzamide derivatives SLC1A2, SLC6A1, KCNT2 SLC6A5 26/4885LMNA 3106/4885TP53 4820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.